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Michael G. S. Shashaty1,4, Aili L. Lazaar5,6, Andrew I. Bayliffe6, Robert J. Gallop4,7, Todd A. Miano4, Thomas G. Dunn1,
Erik Johansson1, Jason Abbott2, Alejandra Jauregui2, Thomas Deiss2, Kathryn Vessel2, Annika Belzer2,
Hanjing Zhuo2, Michael A. Matthay2, Nuala J. Meyer1† and Jason D. Christie1,4†
Abstract
Background: Enrichment strategies improve therapeutic targeting and trial efficiency, but enrichment factors for
sepsis trials are lacking. We determined whether concentrations of soluble tumor necrosis factor receptor-1
(sTNFR1), interleukin-8 (IL8), and angiopoietin-2 (Ang2) could identify sepsis patients at higher mortality risk and
serve as prognostic enrichment factors.
Methods: In a multicenter prospective cohort study of 400 critically ill septic patients, we derived and validated
thresholds for each marker and expressed prognostic enrichment using risk differences (RD) of 30-day mortality as
predictive values. We then used decision curve analysis to simulate the prognostic enrichment of each marker and
compare different prognostic enrichment strategies.
Measurements and main results: An admission sTNFR1 concentration > 8861 pg/ml identified patients with
increased mortality in both the derivation (RD 21.6%) and validation (RD 17.8%) populations. Among
immunocompetent patients, an IL8 concentration > 94 pg/ml identified patients with increased mortality in both
the derivation (RD 17.7%) and validation (RD 27.0%) populations. An Ang2 level > 9761 pg/ml identified patients at
21.3% and 12.3% increased risk of mortality in the derivation and validation populations, respectively. Using sTNFR1
or IL8 to select high-risk patients improved clinical trial power and efficiency compared to selecting patients with
septic shock. Ang2 did not outperform septic shock as an enrichment factor.
Conclusions: Thresholds for sTNFR1 and IL8 consistently identified sepsis patients with higher mortality risk and
may have utility for prognostic enrichment in sepsis trials.
Keywords: Sepsis, Tumor necrosis factor receptors, Interleukin-8, Angiopoietin-2, Biomarkers, Prognostic enrichment
Introduction
Sepsis carries a high mortality and has limited pharmaco-
logic therapy [1]. A pipeline of therapies targeting inflam-
mation, vascular regulation, and immune regulation are in
development, often in tandem with the oncology, auto-
immune, and cardiovascular spheres [2, 3]. However, these
therapies may be associated with adverse effects that tip
the risk-benefit scale in favor of testing the new therapy
among high-risk patients first, to avoid exposing low-risk
patients to a potentially risky therapy. In addition, prior
sepsis trials have been hampered by imprecise estimates of
baseline mortality [4], making interpretation challenging
due to inadequate power.
Several fields have embraced enrichment strategies to
refine patient selection for clinical trials, fostering the
translation of experimental therapies [5–8]. This includes
“prognostic enrichment,” selecting patients with a greater
likelihood of having an outcome, and “predictive
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enrichment,” selecting patients with a greater likelihood of
responding to a specific intervention [9–11]. Despite broad
appeal, enrichment strategies have not been widely applied
in critical care, partly due to a dearth of biomarkers that
might serve as enrichment factors [12–15].
We sought to develop a simple biomarker-based prog-
nostic enrichment method for selecting high-risk patients
for future sepsis trials. We chose three markers, soluble
tumor necrosis factor receptor-1 (sTNFR1), interleukin-8
(IL8), and angiopoietin-2 (Ang2), which are easily measur-
able, associate with sepsis outcomes, and represent path-
ways that are potential targets for sepsis therapy [16–22].
To assess each marker’s prognostic enrichment poten-
tial, we derived concentration thresholds and validated
whether the thresholds consistently identified subjects at
higher mortality risk in two separate cohorts using risk
differences as predictive values. Additionally, we used
decision curve analysis to illustrate the potential benefits
of using each marker to select subjects for clinical trials.
Methods
Study design
Detailed methods are provided in the supplement (Add-
itional file 1). We performed a multicenter prospective co-
hort study enrolling critically ill septic patients admitted
from the emergency departments at the University of Penn-
sylvania (PENN) and the University of California San Fran-
cisco (UCSF). Both cohorts have been described previously
[23, 24]. We chose a priori to enroll 200 subjects at each site
during the same period. The primary outcome was 30-day
mortality. We defined immunocompromise using Acute
Physiology, Age, Chronic Health Evaluation (APACHE) cri-
teria and acute respiratory distress syndrome (ARDS) using
Berlin criteria [25–27]. We defined septic shock as the
receipt of vasopressors and a lactate > 2mmol/l on the day
of intensive care unit (ICU) admission [1]. Each cohort was
approved by its institution’s Institutional Review Board.
Plasma protein measurement
Plasma was obtained as close to ICU bed request as feas-
ible and within 24 h of ICU admission. We measured
sTNFR1, IL8, and Ang2 concentrations using enzyme-
linked immunosorbent assays (R&D Systems).
Statistical methods
We first confirmed each marker’s prognostic value by de-
termining whether the marker was independently associ-
ated with mortality and whether the marker improved
model fit (likelihood-ratio test) and discrimination (area
under the receiver operating characteristic curve [AUC])
when added to a clinical variable model for mortality. We
chose variables that were easily available at admission and
associated with mortality, including age, diabetes, cirrhosis,
immunocompromise, septic shock, and mechanical
ventilation. To operationalize each marker, we split the
population by enrollment site and derived thresholds for
each marker in the derivation population (PENN) using
the Youden method [28]. We performed logistic regression
adjusting for the variables above and calculated standard-
ized risks and risk differences (RD) for mortality between
marker-positive and marker-negative subjects [29]. For
validation, we simulated the effect of simply applying each
marker threshold in the validation population (UCSF)
without clinical variables and focused on whether the un-
adjusted RD fell within the 95% confidence interval (CI) of
the standardized RD in the derivation population, indicat-
ing the marker identified high-risk patients in a similar
fashion while accounting for differences in baseline mor-
tality [30]. We secondarily performed adjusted analyses in
the validation population and tested whether each marker
threshold improved model fit and discrimination when
added to a clinical variable model for mortality in each
population. We tested for effect modification by immuno-
compromised status because differences in inflammatory
pathways have been reported in these patients [24].
Next, we employed decision curve analysis (DCA) to il-
lustrate each marker’s potential as an enrichment factor
(i.e., enroll if marker-positive) [31–33]. The net benefit
(percent true positives − percent false positives) was calcu-
lated across a range of threshold probabilities for mortality,
where the threshold probability represents the mortality
risk a trial would set for enrollment (i.e., enroll patients
with ≥ 35% mortality risk). Decision curves are interpreted
vertically; at each threshold probability, the strategy with
the highest net benefit identifies the highest number of true
positives relative to false positives and thus selects the most
efficient trial population. We compared five enrichment
strategies: (1) enrolling all sepsis patients (no enrichment),
(2) enrolling septic shock patients, (3) enrolling patients
positive for a single marker, (4) enrolling patients positive
for two markers, and (5) enrolling patients whose predicted
mortality using the markers as continuous variables met a
certain threshold [22]. To further illustrate enrichment po-
tential, we calculated sample sizes for a hypothetical trial
testing a therapy with a 20% relative risk reduction of mor-
tality, assuming 90% power. We chose septic shock as our
primary clinical variable enrichment factor because it is
often used to define a high-risk subgroup in sepsis trials
[34, 35]. Secondarily, we evaluated an APACHE II score ≥
20 and a peak lactate ≥ 4mmol/l within the first 24 h as
clinical variable prognostic enrichment factors [26, 36].
Analyses were performed using Stata 15.1; a two-sided
p < 0.05 was considered statistically significant.
Results
Patient characteristics
We enrolled 400 critically ill septic patients (Additional file 2:
Figure S1); baseline characteristics are summarized in
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Table 1. The derivation population was younger, more im-
munocompromised, had less septic shock, more African-
American subjects, and fewer Asian subjects. Both popula-
tions had significant 30-day mortality, 41.0% and 27.0% in
the derivation and validation populations, respectively.
Plasma concentrations of sTNFR1 and IL8 were higher in
the derivation population.
Soluble tumor necrosis factor receptor-1
The plasma sTNFR1 concentration at ICU admission in-
dependently associated with mortality (OR [95% CI] per
1-log increase 1.68 [1.23–2.28]; p = 0.001), and adding the
sTNFR1 concentration to a clinical variable model for
mortality improved model fit and marginally improved
discrimination (Additional file 2: Table S1). The optimal
sTNFR1 threshold in the derivation population was 8861
pg/ml; 46.5% of patients were sTNFR1-positive with a
21.6% (95% CI 8.1–35.2; p = 0.002) adjusted increased ab-
solute risk of mortality. In the validation population,
33.5% were sTNFR1-positive with a 17.8% (95% CI 4.2–
31.3; p = 0.010) unadjusted increased absolute risk of mor-
tality, which was within the 95% CI of the RD in the deriv-
ation population (Table 2). In adjusted analyses, the RD in
the validation population was 13.0% (95% CI 0.3–25.7;
p = 0.045). The sTNFR1 threshold improved model fit and
marginally improved discrimination when added to a
clinical variable model for mortality in each population
(Additional file 2: Table S2).
For prognostic enrichment, enrolling sTNFR1-positive
patients was superior to enrolling patients with septic
shock based on test characteristics (positive predictive
value [PPV] 48.8% vs. 42.3%; negative predictive value
[NPV] 75.8% vs. 72.4%; Additional file 2: Table S3) and
DCA. As shown in Fig. 1a, if a trial sought to enroll pa-
tients with < 25% mortality risk, enrolling all sepsis pa-
tients was optimal and no enrichment was needed.
However, if a trial sought patients at higher mortality
risk, i.e., ≥ 35%, enrolling sTNFR1-positive patients was
superior to enrolling septic shock patients or enrolling
all sepsis patients. In terms of efficiency, if a trial sought
to enroll patients with ≥ 35% mortality risk, enrolling
sTNFR1-positive patients would result in a strategy
equivalent to 18 fewer survivors exposed per 100 pa-
tients enrolled, whereas enrolling septic shock patients
would result in 12 fewer survivors exposed, compared
to enrolling all sepsis patients (Fig. 1b, Additional file 2:
Table S5). In terms of statistical power for a trial
testing a therapy with a 20% relative risk reduction of
mortality, enrolling sTNFR1-positive patients would
reduce the required sample size by 43.3% (N = 1126),
whereas enrolling septic shock patients would reduce
it by 28.1% (N = 1428), compared to enrolling all sep-
sis patients (N = 1986).
Table 1 Characteristics of study population in the derivation and validation cohorts
Variable Derivation (n = 200) Validation (n = 200) p
Age 60 (49.5–69) 67 (59–78) < 0.001
Male gender 110 (55.0%) 105 (52.5%) 0.62
Race
Caucasian 110 (55.0%) 106 (53%) < 0.001
African American 82 (41.0%) 24 (12.0%)
Asian 4 (2.0%) 50 (25.0%)
Other 4 (2.0%) 20 (10.0%)
Diabetes mellitus 59 (29.5%) 57 (28.5%) 0.83
Cirrhosis 20 (10.0%) 17 (8.5%) 0.61
Immunocompromised 95 (47.5%) 27 (13.5%) < 0.001
Pneumonia 78 (39.0%) 104 (52.5%) 0.007
APACHE II 25 (19.5–32.5) 25 (19–33) 0.99
Septic shock at presentation 77 (38.5%) 98 (49.0%) 0.034
Invasive ventilation at presentation 82 (41.0%) 82 (41.0%) 1.0
ARDS 57 (28.5%) 50 (25.3%) 0.47
30-day mortality 82 (41.0%) 54 (27.0%) 0.003
sTNFR1 (pg/ml) 8444 (4332–13,450) 6366 (3232–11,024) 0.004
IL8 (pg/ml) 115.7 (51.2–325.6) 54.7 (23.5–241.0) < 0.001
Ang2 (pg/ml) 13,933 (8747–26,865) 13,894 (7146–24,447) 0.24
Abbreviations: APACHE Acute Physiology, Age and Chronic Health Evaluation, ARDS acute respiratory distress syndrome, sTNFR1 soluble tumor necrosis factor
receptor-1, IL interleukin, Ang2 angiopoietin-2
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Interluekin-8
The plasma IL8 concentration at ICU admission inde-
pendently associated with mortality (OR [95% CI] per 1-
log increase 1.25 [1.09–1.43]; p = 0.001) and improved
model fit and marginally improved discrimination when
added to a clinical variable model for mortality (Add-
itional file 2: Table S1). The optimal IL8 threshold was 94
pg/ml. We found effect modification by immunocom-
promised status on the IL8-mortality association (p =
0.033), with the association driven by immunocompetent
patients (Additional file 2: Table S6). In the derivation
population, 54.3% of immunocompetent patients were
IL8-positive with a 17.7% (95% CI 1.6–33.8; p = 0.031) ad-
justed increased absolute risk of mortality. In the valid-
ation population, 39.3% of immunocompetent subjects
were IL8-positive with a 27.0% (95% CI 13.2–40.8; p <
0.001) unadjusted absolute increased risk of mortality,
which was within the 95% CI of the RD in the derivation
population (Table 2). When adjusted for clinical variables,
the RD in the validation population was 22.1% (95% CI
7.4–36.8; p = 0.003). The IL8 threshold improved model
fit and marginally improved discrimination when added to
a clinical variable model for mortality in each population
(Additional file 2: Table S2).
Among immunocompetent patients, the IL8 threshold
was the superior prognostic enrichment factor compared to
septic shock based on test characteristics (PPV 43.2% vs.
38.4%; NPV 81.7% vs. 77.1%; Additional file 2: Table S4)
and DCA. As shown in Fig. 2a, if a trial sought to enroll pa-
tients with < 20% mortality risk, enrolling all sepsis patients
was optimal; however, if a trial sought patients at higher
mortality risk, i.e., ≥ 35%, enrolling IL8-positive patients
was optimal. For example, if a trial sought to enroll patients
with ≥ 35% mortality risk, enrolling IL8-positive patients
would result in a strategy equivalent to 25 fewer survivors
exposed per 100 patients enrolled, whereas enrolling septic
shock patients would result in 19 fewer survivors exposed,
compared to enrolling all sepsis patients (Fig. 2b, Add-
itional file 2: Table S7). In terms of statistical power, enrol-
ling IL8-positive patients would reduce the required sample
size by 41.8% (N = 1380), whereas enrolling septic shock pa-
tients would reduce it by 30.0% (N = 1660), compared to
enrolling all sepsis patients (N = 2372).
Angiopoietin-2
The plasma Ang2 concentration at ICU admission inde-
pendently associated with mortality (OR [95% CI] per 1-
log increase 1.53 [1.16–2.01]; p = 0.002) and improved
model fit and marginally improved discrimination when
added to a clinical variable model for mortality (Add-
itional file 2: Table S1). The optimal Ang2 threshold was
9761 pg/ml. In the derivation population, 69.5% were
Ang2-positive with a 21.3% (95% CI 7.3–35.3; p = 0.003)
adjusted increased absolute risk of mortality. In the val-
idation population, 63.5% were Ang2-positive with a
12.3% (95% CI 0.2–24.4; p = 0.046) unadjusted increased
absolute risk of mortality (Table 2). In adjusted analyses,
the RD in the validation population was 10.8% (95% CI
− 1.1–22.6; p = 0.075). The Ang2 threshold did not con-
sistently improve model fit and discrimination (Add-
itional file 2: Table S2) and was not consistently superior
to septic shock for prognostic enrichment (Fig. 3, Add-
itional file 2: Tables S3 and S8).
Combinatorial and secondary models
Secondarily, we evaluated the combined enrichment poten-
tial of sTNFR1 and IL8. Positivity for both sTNFR1 and IL8
improved discrimination to a similar degree as the individ-
ual markers (Additional file 2: Table S9), and as an enrich-
ment factor performed similarly to sTNFR1 alone and
slightly outperformed IL8 alone (Additional file 2: Figure
S2). This may be due to the effect modification of
Table 2 Risks and risk differences of 30-day mortality categorized by marker positivity for soluble tumor necrosis factor receptor-1
(sTNFR1), interleukin-8 (IL8), and angiopoietin-2 (Ang2), in the derivation (N = 200) and validation (N = 200) cohorts. Standardized risks
and risk differences are reported for the derivation cohort, adjusted for age, cirrhosis, immunocompromised state, septic shock at
presentation, and mechanical ventilation at presentation. Crude risks and risk differences are reported for the validation cohort. The
IL8 analysis is limited to immunocompetent patients (N = 105 in derivation cohort, N = 173 in validation cohort)
Marker and site Number (%) of subjects
above threshold
30-day mortality (95% CI)
if below threshold
30-day mortality (95% CI)
if above threshold
Risk difference of 30-day mortality
(95% CI) if above threshold
p
sTNFR1 > 8861 pg/ml
Derivation 93 (46.5%) 30.4% (21.6, 39.2) 52.0% (42.3, 61.7) 21.6% (8.1, 35.2) 0.002
Validation 67 (33.5%) 21.1% (14.1, 28.0) 38.8% (27.1, 50.5) 17.8% (4.2, 31.3) 0.010
IL8 > 94 pg/ml
Derivation 57 (54.3%) 23.2% (11.8, 34.6) 40.9% (29.8, 52.0) 17.7% (1.6, 33.8) 0.031
Validation 68 (39.3%) 18.9% (11.9, 25.8) 44.1% (32.3, 55.9) 27.0% (13.2, 40.8) < 0.001
Ang2 > 9761 pg/ml
Derivation 139 (69.5%) 25.8% (14.6, 37.1) 47.1% (39.3, 54.9) 21.3% (7.3, 35.3) 0.003
Validation 127 (63.5%) 19.2% (10.2, 28.2) 31.5% (23.4, 39.6) 12.3% (0.2, 24.4) 0.046
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immunocompromised status on the IL8-mortality associ-
ation, as positivity for both sTNFR1 and IL8 was superior
when restricted to immunocompetent patients (Add-
itional file 2: Figure S3). Using the predicted mortality from
sTNFR1 and IL8 concentrations as continuous variables
yielded similar discrimination as the individual marker
thresholds, similar enrichment as positivity for sTNFR1
Fig. 1 a Net benefit curves of three clinical trial enrollment strategies:
enrolling all sepsis patients (black line), enrolling patients with septic
shock (blue line), and enrolling sTNFR1 positive patients (red line). The
x-axis represents the threshold probability, which is the probability of
mortality that a hypothetical trial would require for enrollment. The y-
axis is the net benefit, which represents the tradeoff between true
positives and false positives, and is calculated as (true positives/n) −
(false positive/n) × (pt/1 − pt), where pt is the threshold probability. The
net benefit varies with the threshold probability since it reflects the
relative harms of missing non-survivors (false negatives) and enrolling
too many survivors (false positives). We focused on threshold
probabilities between 15 and 50%, because enrichment is unnecessary
at low thresholds given baseline mortality, and we reasoned that
patients with > 50% mortality risk may be excluded from trials because
they may be less likely to respond to therapy. Net benefit curves are
interpreted vertically; at each threshold probability, the strategy with
the highest net benefit is the optimal strategy for enriching a trial with
high-risk subjects. For example, if a trial sought to enroll patients with
at least 35% mortality risk (dotted vertical line), enrolling only sTNFR1-
positive patients is the optimal strategy. b Intervention curves
comparing enrolling all sepsis patients (reference, not shown), enrolling
patients with septic shock (blue line), and enrolling sTNFR1 positive
patients (red line). Intervention curves are an alternative representation
of net benefit and are also interpreted vertically. The y-axis represents
the number of survivors that avoid the intervention, which in this case
is enrollment and exposure to unproven therapy. At a threshold
probability of 35%, enrolling sTNFR1-positive patients would lead to a
greater reduction in the number of survivors unnecessarily exposed
compared to enrolling patients with septic shock
Fig. 2 a Net benefit curves of three clinical trial enrollment strategies,
enrolling all sepsis patients (black line), enrolling patients with septic
shock (blue line), and enrolling IL-8-positive patients (red line), in a
population restricted to immunocompetent patients. The x-axis
represents the threshold probability, which is the probability of sepsis
mortality that a hypothetical trial would require for enrollment. The y-
axis is the net benefit, which represents the tradeoff between true
positives and false positives, and is described further in the legend of
Fig. 1. The net benefit curves are interpreted vertically, such that at
each threshold probability, the strategy with the highest net benefit is
the optimal strategy for enriching a trial with high-risk subjects. For
example, if a trial sought to enroll patients with at least 35% mortality
risk (dotted vertical line), enrolling only IL-8 positive patients is the
optimal strategy. b Intervention curves comparing enrolling all sepsis
patients (reference, not shown), enrolling patients with septic shock
(blue line), and enrolling IL-8-positive patients (red line), in a population
restricted to immunocompetent patients. The y-axis represents the
number of survivors that avoid the intervention, which in this case is
enrollment and exposure to unproven therapy. Intervention curves are
also interpreted vertically. For example, at a threshold probability of
35%, enrolling only IL-8-positive patients would lead to a greater
reduction in the number of survivors unnecessarily exposed compared
to enrolling patients with septic shock
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alone, and slightly superior enrichment as positivity for IL8
alone (Additional file 2: Table S9, Figure S4).
For our secondary clinical variable enrichment methods,
an APACHE II score ≥ 20 yielded superior enrichment
compared to sTNFR1 positivity and IL8 positivity at lower
mortality thresholds, whereas sTNFR1 positivity was
superior to an APACHE II ≥ 20 at mortality thresholds
above 33% and IL8 positivity was superior at mortality
thresholds above 36% (Additional file 2: Table S3, Figure
S5). Positivity for sTNFR1 outperformed peak lactate ≥ 4
mmol/l, whereas IL8 positivity performed similarly (Add-
itional file 2: Table S3, Figure S6).
Discussion
We found that plasma sTNFR1 and IL8 thresholds con-
sistently identified subjects at higher mortality risk in two
distinct populations of critically ill septic patients. We also
demonstrated that sTNFR1 and IL8 could potentially
serve as prognostic enrichment factors for sepsis trials. By
selecting high-risk patients, using these markers could im-
prove trial efficiency and power and reduce the number of
survivors unnecessarily exposed to potentially risky ther-
apies even more so than using septic shock.
Our results are consistent with a study by Mikacenic
et al., which found that using sTNFR1 and IL8 concentra-
tions in a continuous fashion could risk stratify sepsis
patients [22]. Our data build on these findings by demon-
strating that thresholds of these markers could provide a
simpler method to refine trial enrollment, that the individ-
ual markers have enrichment potential and perform simi-
larly to combined models, that the markers are superior to
using septic shock for enrichment, and that the markers
have prognostic value in patients with higher illness severity
and mortality. Our data also reveal potential limitations of
using IL8 for enrichment in immunocompromised patients,
given our findings that the IL8 threshold was associated
with higher mortality in immunocompetent subjects but
not immunocompromised subjects.
Although we demonstrated that the Ang2 threshold
identified high-risk patients, it did not appear to have
utility over using septic shock for prognostic enrich-
ment. This may be due to the association of dysregulated
Ang2 with septic shock [37], suggesting both variables
identified a similar high-risk subgroup and thus provided
similar enrichment.
Our data add to the growing body of literature
highlighting the potential benefits of biomarker-based en-
richment for critical care trials. Recent sepsis trials have
demonstrated a discrepancy between the estimated mor-
tality based on clinical criteria and observed mortality [4,
38], which could result in inadequate power to detect a
benefit of a tested therapy. Despite differing baseline mor-
tality at our two sites, sTNFR1 positivity consistently iden-
tified subjects with at least 17.8% higher mortality risk,
and IL8 positivity consistently identified immunocompe-
tent patients with at least 17.7% higher mortality risk.
These markers could potentially provide a method to en-
sure adequate baseline mortality in future trials.
Our study has several strengths. We performed a two-
center cohort study, enrolling two distinct populations
Fig. 3 a Net benefit curves of three clinical trial enrollment
strategies: enrolling all sepsis patients (black line), enrolling patients
with septic shock (blue line), and enrolling Ang-2 positive patients
(red line). The x-axis represents the threshold probability, which is
the probability of sepsis mortality that a hypothetical trial would
require for enrollment. The y-axis is the net benefit, which represents
the tradeoff between true positives and false positives, and is
described further in the legend of Fig. 1. The net benefit curves are
interpreted vertically, such that at each threshold probability, the
strategy with the highest net benefit is the optimal strategy for
enriching a trial with high-risk subjects. For example, if a trial sought
to enroll patients with at least 35% mortality risk (dotted vertical
line), enrolling only Ang-2 positive patients had a similar net benefit
to enrolling only patients with septic shock. b Intervention curves
comparing enrolling all sepsis patients (reference, not shown),
enrolling patients with septic shock (blue line), and enrolling Ang-2
positive patients (red line). Intervention curves are an alternative
representation of net benefit. The y-axis represents the number of
survivors that avoid the intervention, which in this case is enrollment
and exposure to unproven and potentially risky therapy. Intervention
curves are also interpreted vertically. For example, at a threshold
probability of 35%, enrolling only Ang-2-positive patients led to a
similar reduction in the number of survivors exposed when
compared to enrolling only patients with septic shock
Anderson et al. Critical Care          (2019) 23:400 Page 6 of 9
with a wide distribution of ages, diverse racial makeup,
and differences in illness severity. Our use of plasma
thresholds simulated operationalizing the markers as sim-
ple methods for trial enrichment. The biomarkers were
measured as close to admission as possible, demonstrating
they have prognostic relevance in early sepsis when most
trials seek to enroll patients. We used risk differences to
provide easily interpretable predictive values and
employed decision curves, a novel method to evaluate bio-
markers [39, 40], to compare enrichment strategies.
Our study also has limitations. Although we successfully
derived and validated thresholds of each marker that con-
sistently identified patients at higher risk of mortality in
both cohorts, the improvements in discrimination when
the markers were added to clinical variables were relatively
incremental. In addition, although the marker thresholds
outperformed an APACHE-based method at higher mor-
tality thresholds, the APACHE-based method was superior
at lower mortality thresholds. This may ultimately limit
each marker’s utility as simple prognostic enrichment fac-
tors, given the APACHE score can be obtained from clin-
ical data at no additional cost, and several barriers still
need to be addressed to improve the feasibility and practi-
cality of employing biomarker enrichment strategies, such
as advances in rapid testing and validation of testing for
clinical use [15]. In addition, we identified that the IL8
threshold’s utility as a prognostic enrichment factor was
limited to immunocompetent patients, further limiting its
potential as a sole enrichment factor given the frequency of
sepsis among immunocompromised patients and because
immune impairment may be unrecognized at the time of
ICU admission. Although we selected these markers
because of their prior association with sepsis mortality and
their representation of pathways for which therapies are
being developed, using these markers for prognostic en-
richment may inadvertently select mechanistically distinct
subgroups, which could limit the generalizability of clinical
trials that use these markers for prognostic enrichment.
Furthermore, other plasma markers and clinical variable
enrichment methods may deserve consideration as prog-
nostic enrichment factors in future studies.
We also recognize that the confidence intervals for the
risk differences in mortality were moderately wide. How-
ever, the goal of using risk differences as predictive values
was not for individual prognostication, but only to guide
trial enrollment. Given the strength of the association in
two distinct cohorts and the decision curve analysis demon-
strating the potential value of using each marker when
compared to clinical variable methods, these markers ap-
pear to have potential as prognostic enrichment factors.
Larger studies may be needed to confirm our findings and
refine the use of these markers as prognostic enrichment
factors, which may include further refining the biomarker
thresholds. It is also important to note that the mortality
among marker-negative patients (false negatives) was not
inconsequential. However, one benefit of DCA is that it
does not make assumptions about the relative harms of
false positives and false negatives, leaving it to the trialist to
define their importance by choosing the threshold probabil-
ity. If a trialist’s priority was minimizing the exclusion of
non-survivors (i.e., minimizing false negatives), as would be
the case for a trial of an inexpensive, low-risk therapy with
a high likelihood of benefit, the trialist would set a low mor-
tality threshold (i.e., enroll all patients with sepsis). Alterna-
tively, if a trialist was concerned about potentially high-risk
side effects from an experimental therapy, they might con-
sider it necessary to exclude patients with low mortality risk
and set a higher threshold even though some non-survivors
would be excluded. Thus, the relative importance of false
negatives and false positives varies based on the probability
threshold, and the DCA provides a method for comparing
enrollment strategies at each threshold.
Lastly, an important limitation of our study is that we
were unable to evaluate the predictive enrichment potential
of sTNFR1, IL8, and Ang2. Sepsis is a heterogeneous syn-
drome with myriad pathways contributing to organ dys-
function and death. Several recent studies have highlighted
heterogeneity in the treatment effect of therapies in sepsis
and suggest biomarkers could identify patients more likely
to respond to therapy. In a prospective trial, sepsis patients
with higher baseline interleukin-6 levels appeared more
likely to respond to anti-tumor necrosis factor therapy [41].
In retrospective analyses, biomarker-based strategies identi-
fied heterogeneity in treatment effect in sepsis trials of re-
combinant human interleukin-1 receptor antagonist and
anti-TNF-α antibody therapy [42, 43]. Similarly, studies have
shown heterogeneity in treatment effect among patients
with a hyperinflammatory subphenotype of ARDS [44–46].
Because sTNFR1, IL8, and Ang2 reflect pathways that are
dysregulated in sepsis and for which therapies are being in-
vestigated, such as monoclonal antibodies targeting IL8 and
TNF [16–18], they should be evaluated as predictive enrich-
ment factors for their designated therapies in future trials.
Conclusions
In summary, we found that plasma levels of sTNFR1
and IL8 consistently identified sepsis patients at higher
risk of mortality and might be useful as prognostic en-
richment factors in future trials by improving trial effi-
ciency and power and reducing the number of survivors
unnecessarily exposed to potentially risky therapy.
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